Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
NurExone Biologic ( (TSE:NRX) ) has issued an announcement.
NurExone Biologic Inc. has formed a U.S.-based subsidiary, Exo-Top Inc., to advance the production and commercialization of exosomes, a promising drug delivery system. This strategic move allows NurExone to independently manage its exosome supply chain, enhancing cost efficiency and strategic flexibility, while opening new market opportunities and revenue streams by supplying GMP-grade exosomes to various entities. Exo-Top’s establishment in Nevada provides proximity to strategic partners and access to the U.S. biopharma ecosystem, positioning NurExone as a significant player in the exosome-based drug delivery industry.
More about NurExone Biologic
NurExone Biologic Inc. is a pharmaceutical company listed on the TSX Venture Exchange and OTCQB, focusing on the development of biologically guided exosome-based therapies. Their primary product, ExoPTEN, targets acute spinal cord injury and has shown promising results in preclinical trials. The company aims to provide innovative solutions for minimally invasive targeted drug delivery.
YTD Price Performance: -6.56%
Average Trading Volume: 44,512
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$31.63M
Find detailed analytics on NRX stock on TipRanks’ Stock Analysis page.
